Vincent J. Angotti

Mr. Angotti brings more than 2 decades of experience leading executive and commercial teams at public and private life sciences companies. Prior to joining Talphera in March 2017, he was the Chief Executive Officer of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for neuropathic pain and other neurologic disorders. During his tenure at XenoPort, Mr. Angotti led the acquisition of Horizant from GSK and implemented a successful rebranding and relaunch strategy that led to XenoPort’s acquisition by Arbor Pharmaceuticals, LLC, in 2016 for $0.5 billion.

Before joining XenoPort, Mr. Angotti held senior commercial positions at Reliant Pharmaceuticals, Inc., from 2001 to 2008, where he successfully launched several products, including Lovaza. In his role as Senior Vice President of Sales and Marketing at Reliant, Mr. Angotti was integrally involved in the company’s business development strategy that concluded with Reliant’s acquisition by GSK in 2007 for $1.7 billion. He began his career in the life sciences industry at Novartis Pharmaceuticals Corp., where he worked from 1991 to 2001 in sales and operations positions of increasing responsibility.

Mr. Angotti earned a Bachelor of Science degree with a concentration in business management from Cornell University in 1990 and a Master of Business Administration degree with honors from Columbia University in 2000.